FARMINGTON, Conn., June 5, 2013 /PRNewswire-iReach/ -- From Global Information and MCD Group, a new report "Early Stage Drug Delivery Technologies" profiles 62 start-ups and small companies that have interest in forming new partnerships or receiving funding to enable further development and eventual commercialization of their drug delivery technologies. All of the companies investigated are developing technologies that could potentially transform drug delivery in one or more therapeutic areas.
Lauren Sciences LLC is one of the 62 start-ups and small companies that are expected to gain momentum as they advance their drug delivery technologies and produce significant clinical data. At Lauren Sciences, their proprietary V-Smart V-SmartTM nanovesicle technology has already demonstrated the ability to cross the blood-brain barrier (BBB) and deliver encapsulated contents directly to the brain.
Benefits of reading this report:
The following list provides a sampling of the start-ups and small companies profiled in this report by therapeutic category.
Emerging companies developing breakthrough treatments for cancer: Blend Therapeutics, Centrose, Intensity Therapeutics
Emerging companies developing proprietary devices for subcutaneous drug delivery: scPharmaceuticals, Ratio, Inc.
Emerging companies focused on ophthalmic drug delivery technologies:Clearside Biomedical, Corinthian Opthalmic, iVeena
Emerging companies focused on effective delivery technology for large molecular weight drugs such as antibody-based therapeutics, proteins, and peptides: Entrega, Extend, Biosciences, Solstice Biologics
Gain access to all of the 62 emerging company profiles by ordering the report online from our website: http://www.giiresearch.com/report/mcd269546-early-stage-drug-delivery-technologies-profiles.html
Genome to Drug Lead with Big Data Approach
June 19 – 21, 2013 | Boston, MA | The Revere Hotel
Structure-Based Drug Design 2013 is coming up in two weeks. This year's conference will feature developments in insilico technology, experimental approaches for accurately predicting and modeling protein structures in structure-based drug design, and examples of successful applications of approaches to genome-to-drug lead investigations.
>> Learn more at http://www.giiconference.com/chi256968-2013/
Register online at https://www.giiresearch.com/conference/en/order/256968. We hope to see you June 19 in Boston!
Event Organizers: Need to reach biodefense and biomedical technology executives in Asia?
GlobalReach currently provides event marketing services for over 300 events annually in Japanese, Korean, and both Simplified and Traditional Chinese, reaching thousands of sponsors and attendees. A portfolio of their work and pricing information can be found at www.globalreachevent.com.
About GlobalReach Offering affordable fixed-price translation, localization, and conference marketing services, GlobalReach bridges the gap between cultures to connect organizers with the fastest growing markets on the planet. For over a decade, Global Information Inc, through our GlobalReach event service, has connected conference and event organizers in the West with attendees, exhibitors, and sponsors in the East.
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 400 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 30 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
Media Contact: Joe Malley Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE Global Information, Inc.|
Copyright©2012 PR Newswire.
All rights reserved